Comparison of the Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Obese Patients With Kidney Disease: a Single Center, Prospective, Exploratory Study
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Dapagliflozin (Primary) ; Losartan (Primary) ; Semaglutide (Primary) ; Sitagliptin (Primary) ; Valsartan (Primary)
- Indications Obesity; Renal failure
- Focus Therapeutic Use
Most Recent Events
- 11 Apr 2024 New trial record